Canada approves Imcivree for hypothalamic obesity in ages 4+

Rhythm Pharmaceuticals amended its exclusive license agreement with LG Chem for Bivamelagon, including $350M in fixed payments over 4 years and a 1% royalty. The company also secured a $750M term loan from KKR and Blackstone at SOFR+4.60%.

Rhythm Pharmaceuticals (RYTM) will pay LG Chem $350M over four years, reducing royalties to 1%. The company also secured a $750M loan facility, with $500M committed, expected to close Nov. 6, 2026, subject to conditions.

Rhythm Pharmaceuticals (RYTM) secured a $750M loan facility, with $500M committed, led by KKR’s HealthCare Royalty and Blackstone. The company also amended its license agreement with LG Chem for bivamelagon, an investigational MC4R agonist, including additional fixed payments. Rhythm aims to advance the drug's development for rare obesity diseases, potentially creating long-term value for shareholders.

Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for treating acquired hypothalamic obesity. The drug, approved by Japan's Ministry of Health, showed an 18.8% placebo-adjusted BMI reduction in trials. It's the first approved therapy for this condition in Japan, with 5,000-8,000 potential patients. RYTM also markets the drug in the U.S. and Europe for similar indications.

Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for acquired hypothalamic obesity after regulatory approval and NHI listing. This is the first approved therapy in Japan for this condition, marking the company's geographic expansion of setmelanotide. Investors will watch for uptake metrics and revenue contributions in future quarters.

Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for acquired hypothalamic obesity, the first approved treatment for this condition in the country. The drug was included in Japan's National Health Insurance list, following MHLW approval in August. Rhythm estimates 5,000-8,000 people in Japan may have this condition.